211 related articles for article (PubMed ID: 26259955)
1. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
5. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Mak G; Soria JC; Blagden SP; Plummer R; Fleming RA; Nebot N; Zhang J; Mazumdar J; Rogan D; Gazzah A; Rizzuto I; Greystoke A; Yan L; Tolson J; Auger KR; Arkenau HT
Br J Cancer; 2019 May; 120(10):975-981. PubMed ID: 30992546
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
[TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
Voon PJ; Chen EX; Chen HX; Lockhart AC; Sahebjam S; Kelly K; Vaishampayan UN; Subbiah V; Razak AR; Renouf DJ; Hotte SJ; Singh A; Bedard PL; Hansen AR; Ivy SP; Wang L; Stayner LA; Siu LL; Spreafico A
J Exp Clin Cancer Res; 2022 Feb; 41(1):51. PubMed ID: 35130943
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
Ikeda M; Ioka T; Fukutomi A; Morizane C; Kasuga A; Takahashi H; Todaka A; Okusaka T; Creasy CL; Gorman S; Felitsky DJ; Kobayashi M; Zhang F; Furuse J
Cancer Sci; 2018 Jan; 109(1):215-224. PubMed ID: 29121415
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Infante JR; Somer BG; Park JO; Li CP; Scheulen ME; Kasubhai SM; Oh DY; Liu Y; Redhu S; Steplewski K; Le N
Eur J Cancer; 2014 Aug; 50(12):2072-81. PubMed ID: 24915778
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract][Full Text] [Related]
20. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Coupe N; Corrie P; Hategan M; Larkin J; Gore M; Gupta A; Wise A; Suter S; Ciria C; Love S; Collins L; Middleton MR
Eur J Cancer; 2015 Feb; 51(3):359-66. PubMed ID: 25542057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]